Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Lowe, Jeovannaa | Kadakia, Feni K.a | Zins, Jonathan G.a | Haupt, Michaela | Peczkowski, Kyra K.a | Rastogi, Nehaa | Floyd, Kyle T.a | Gomez-Sanchez, Elise P.b | Gomez-Sanchez, Celso E.c | Elnakish, Mohammad T.a; d | Rafael-Fortney, Jill A.a; 1; * | Janssen, Paul M.L.a; 1
Affiliations: [a] Department of Physiology & Cell Biology, College of Medicine, The Ohio State University, Columbus, OH, USA | [b] Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS, USA | [c] Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA | [d] Department of Pharmacology & Toxicology, Faculty of Pharmacy, Helwan University, Cairo, Egypt
Correspondence: [*] Correspondence to: Jill A. Rafael-Fortney, Department of Physiology & Cell Biology, College of Medicine, The Ohio State University, 410 Hamilton Hall, 1645 Neil Avenue. Columbus, OH 43210, USA. Tel.: +1 614 292 7043; E-mail: rafael-fortney.1@osu.edu.
Note: [1] These authors contributed equally.
Abstract: Background:Mineralocorticoid receptor antagonists added to angiotensin converting enzyme inhibitors have shown preclinical efficacy for both skeletal and cardiac muscle outcomes in young sedentary dystrophin-deficient mdx mice also haploinsufficient for utrophin, a Duchenne muscular dystrophy (DMD) model. The mdx genotypic DMD model has mild pathology, making non-curative therapeutic effects difficult to distinguish at baseline. Since the cardiac benefit of mineralocorticoid receptor antagonists has been translated to DMD patients, it is important to optimize potential advantages for skeletal muscle by further defining efficacy parameters. Objective:We aimed to test whether therapeutic effects of mineralocorticoid receptor antagonists added to angiotensin converting enzyme inhibitors are detectable using three different reported methods of exacerbating the mdx phenotype. Methods:We tested treatment with lisinopril and the mineralocorticoid receptor antagonist spironolactone in: 10 week-old exercised, 1 year-old sedentary, and 5 month-old isoproterenol treated mdx mice and performed comprehensive functional and histological measurements. Results:None of the protocols to exacerbate mdx phenotypes resulted in dramatically enhanced pathology and no significant benefit was observed with treatment. Conclusions:Since endogenous mineralocorticoid aldosterone production from immune cells in dystrophic muscle may explain antagonist efficacy, it is likely that these drugs work optimally during the narrow window of peak inflammation in mdx mice. Exercised and aged mdx mice do not display prolific damage and inflammation, likely explaining the absence of continued efficacy of these drugs. Since inflammation is more prevalent in DMD patients, the therapeutic window for mineralocorticoid receptor antagonists in patients may be longer.
Keywords: Mineralocorticoid receptors, Duchenne muscular dystrophy, spironolactone, lisinopril, mdx mice
DOI: 10.3233/JND-180323
Journal: Journal of Neuromuscular Diseases, vol. 5, no. 3, pp. 295-306, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl